Assessing bioequivalence of generic antiepilepsy drugs
- 29 June 2011
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 70 (2) , 221-228
Abstract
Objective: Patients with epilepsy are often concerned that switching between brand‐name and generic formulations of antiepilepsy drugs (AEDs) may cause clinically significant changes in plasma drug concentrations. We assessed bioequivalence (BE) studies for approved generic AEDs to evaluate US Food and Drug Administration claims that: (1) generic AEDs are accurate copies of reference formulations; (2) delivery of reference formulations may be as variable as generic AEDs and so provide no increased benefit; and (3) switches between generic AED formulations are safe and effective.Methods: We determined differences in 90% confidence interval limits for total drug exposure (AUC0‐t) and peak concentration (Cmax) ratios of generic and reference formulations during fasting and fed BE studies. We simulated BE between generic formulations after adjusting for reference values.Results: AUC0‐t values of approved reference and generic formulations differed by 15% for 39%. AEDs with low bioavailability and solubility (eg, oxcarbazepine) had the greatest variability in BE.Interpretation: Most generic AED products provide total drug delivery (AUC) similar to reference products; differences in peak concentrations between formulations are more common. Switches between generic AED products may cause greater changes in plasma drug concentrations than generic substitutions of reference products. ANN NEUROL 2011Keywords
This publication has 23 references indexed in Scilit:
- Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug DevelopmentThe AAPS Journal, 2011
- Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative ValueEpilepsy Currents, 2009
- The risks and costs of multiple-generic substitution of topiramateNeurology, 2009
- Substitution of anticonvulsant drugsTherapeutics and Clinical Risk Management, 2009
- Case‐control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changesEpilepsia, 2009
- Generic Antiepileptic Drugs: Current Controversies and Future DirectionsEpilepsy Currents, 2008
- Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic StrategiesEpilepsia, 2008
- Exposure–response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tabletsBritish Journal of Clinical Pharmacology, 2007
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Improved CNS tolerability following conversion from immediate- to extended-release carbamazepineActa Neurologica Scandinavica, 2004